{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:54:20Z","timestamp":1777953260441,"version":"3.51.4"},"reference-count":25,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2016,5,1]]},"DOI":"10.1188\/16.onf.389-393","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T14:54:29Z","timestamp":1461336869000},"page":"389-393","source":"Crossref","is-referenced-by-count":8,"title":["Genetic Influence on Chemotherapy-Induced Nausea and Vomiting: A Narrative Review"],"prefix":"10.1188","volume":"43","author":[{"given":"Jason","family":"Kiernan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,5,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Babaoglu, M.O., Bayar, B., Aynacioglu, A.S., Kerb, R., Abali, H., Celik, I., & Bozkurt, A. (2005). Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists. Clinical Pharmacology and Therapeutics, 78, 619\u2013626. doi:10.1016\/j.clpt.2005.08.015","DOI":"10.1016\/j.clpt.2005.08.015"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bayo, J., Fonseca, P.J., Hernando, S., Servitja, S., Calvo, A., Falagan, S., . . . Barnadas, A. (2012). Chemotherapy-induced nausea and vomiting: Pathophysiology and therapeutic principles. Clinical and Translational Oncology, 14, 413\u2013422. doi:10.1007\/s12094-012-0818-y","DOI":"10.1007\/s12094-012-0818-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Fasching, P.A., Kollmannsberger, B., Strissel, P.L., Niesler, B., Engel, J., Kreis, H., . . . Strick, R. (2008). Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Journal of Cancer Research and Clinical Oncology, 134, 1079\u20131086. doi:10.1007\/s00432-008-0387-1","DOI":"10.1007\/s00432-008-0387-1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Hammer, C., Fasching, P.A., Loehberg, C.R., Rauh, C., Ekici, A.B., Jud, S.M., . . . Niesler, B. (2010). Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. Pharmacogenomics, 11, 943\u2013950. doi:10.2217\/pgs.10.67","DOI":"10.2217\/pgs.10.67"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Hassan, B.A., & Yusoff, Z.B. (2011). Genetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pacific Journal of Cancer Prevention, 12, 185\u2013191. doi:10.1007\/bf01208844","DOI":"10.1007\/BF01208844"},{"key":"6","doi-asserted-by":"crossref","unstructured":"He, H., Yin, J.Y., Xu, Y.J., Li, X., Zhang, Y., Liu, Z.G., . . . Liu, Z.Q. (2014). Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting. Clinical Therapeutics, 36, 1242\u20131252. doi:10.1016\/j.clinthera.2014.06.016","DOI":"10.1016\/j.clinthera.2014.06.016"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Hesketh, P.J., Aapro, M., Street, J.C., & Carides, A.D. (2010). Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Supportive Care in Cancer, 18, 1171\u20131177. doi:10.1007\/s00520-009-0737-9","DOI":"10.1007\/s00520-009-0737-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Hesketh, P.J., Grunberg, S.M., Herrstedt, J., de Wit, R., Gralla, R.J., Carides, A.D., . . . Horgan, K.J. (2006). Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: Effect of gender on treatment response. Supportive Care in Cancer, 14, 354\u2013360. doi:10.1007\/s00520-005-0914-4","DOI":"10.1007\/s00520-005-0914-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Hesketh, P.J., Kris, M.G., Grunberg, S.M., Beck, T., Hainsworth, J.D., Harker, G., . . . Lindley, C.M. (1997). Proposal for classifying the acute emetogenicity of cancer chemotherapy. Journal of Clinical Oncology, 15, 103\u2013109.","DOI":"10.1200\/JCO.1997.15.1.103"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Huang, P., Zhu, B., Wang, L.S., Ouyang, D.S., Huang, S.L., Chen, X.P., & Zhou, H.H. (2003). Relationship between CYP3A activity and breast cancer susceptibility in Chinese Han women. European Journal of Clinical Pharmacology, 59, 471\u2013476. doi:10.1007\/s00228-003-0649-4","DOI":"10.1007\/s00228-003-0649-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Jonker, J.W., Wagenaar, E., Van Eijl, S., & Schinkel, A.H. (2003). Deficiency in the organic cation transporters 1 and 2 (Oct1\/Oct2 [Slc22a1\/Slc22a2]) in mice abolishes renal secretion of organic cations. Molecular and Cellular Biology, 23, 7902\u20137908. doi:10.1128\/mcb.23.21.7902-7908.2003","DOI":"10.1128\/MCB.23.21.7902-7908.2003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P.B., . . . Brockm\u00f6ller, J. (2002). Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. Journal of Clinical Oncology, 20, 2805\u20132811. doi:10.1200\/jco.2002.09.064","DOI":"10.1200\/JCO.2002.09.064"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kaiser, R., Tremblay, P.B., Sezer, O., Possinger, K., Roots, I., & Brockm\u00f6ller, J. (2004). Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics, 14, 271\u2013278. doi:10.1097\/00008571-200405000-00001","DOI":"10.1097\/00008571-200405000-00001"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Niesler, B., Walstab, J., Combrink, S., M\u00f6ller, D., Kapeller, J., Rietdorf, J., . . . Br\u00fcss, M. (2007). Characterization of the novel human serotonin receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E. Molecular Pharmacology, 72, 8\u201317. doi:10.1124\/mol.106.032144","DOI":"10.1124\/mol.106.032144"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Perwitasari, D.A., Wessels, J.A., van der Straaten, R.J., Baak-Pablo, R.F., Mustofa, M., Hakimi, M., . . . Guchelaar, H.J. (2011). Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. Japanese Journal of Clinical Oncology, 41, 1168\u20131176. doi:10.1093\/jjco\/hyr117","DOI":"10.1093\/jjco\/hyr117"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Pirri, C., Katris, P., Trotter, J., Bayliss, E., Bennett, R., & Drummond, P. (2011). Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: A prospective, longitudinal, observational study. Supportive Care in Cancer, 19, 1549\u20131563. doi:10.1007\/s00520-010-0982-y","DOI":"10.1007\/s00520-010-0982-y"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Rais, N., Chawla, Y.K., & Kohli, K.K. (2006). CYP3A phenotypes and genotypes in North Indians. European Journal of Clinical Pharmacology, 62, 417\u2013422. doi:10.1007\/s00228-006-0105-3","DOI":"10.1007\/s00228-006-0105-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Roscoe, J.A., Morrow, G.R., Colagiuri, B., Heckler, C.E., Pudlo, B.D., Colman, L., . . . Jacobs, A. (2010). Insight in the prediction of chemotherapy-induced nausea. Supportive Care in Cancer, 18, 869\u2013876. doi:10.1007\/s00520-009-0723-2","DOI":"10.1007\/s00520-009-0723-2"},{"key":"19","unstructured":"Sachse, C., Brockm\u00f6ller, J., Bauer, S., & Roots, I. (1997). Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. American Journal of Human Genetics, 60, 284\u2013295."},{"key":"20","doi-asserted-by":"crossref","unstructured":"Sakaeda, T., Nakamura, T., & Okumura, K. (2002). MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biological and Pharmaceutical Bulletin, 25, 1391\u20131400. doi:10.1248\/bpb.25.1391","DOI":"10.1248\/bpb.25.1391"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Tremblay, P.B., Kaiser, R., Sezer, O., Rosler, N., Schelenz, C., Possinger, K., . . . Brockmoller, J. (2003). Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. Journal of Clinical Oncology, 21, 2147\u20132155. doi:10.1200\/jco.2003.05.164","DOI":"10.1200\/JCO.2003.05.164"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Tzvetkov, M.V., Saadatmand, A.R., Bokelmann, K., Meineke, I., Kaiser, R., & Brockm\u00f6ller, J. (2012). Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT3 antagonists tropisetron and ondansetron. Pharmacogenomics Journal, 12, 22\u201329. doi:10.1038\/tpj.2010.75","DOI":"10.1038\/tpj.2010.75"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Ward, M.B., Kotasek, D., & McKinnon, R.A. (2008). Investigation of HRT3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy. Pharmacogenomics, 9, 1027\u20131033. doi:10.2217\/14622416.9.8.1027","DOI":"10.2217\/14622416.9.8.1027"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Warr, D.G., Street, J.C., & Carides, A.D. (2011). Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Supportive Care in Cancer, 19, 807\u2013813. doi:10.1007\/s00520-010-0899-5","DOI":"10.1007\/s00520-010-0899-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Zoto, T., Kilickap, S., Yasar, U., Celik, I., Bozkurt, A., & Babaoglu, M.O. (2015). Improved anti-emetic efficacy of 5-HT3 receptor antagonists in cancer patients with genetic polymorphisms of ABCB1 (MDR1) drug transporter. Basic and Clinical Pharmacology and Toxicology, 4, 354\u2013360. doi:10.1111\/bcpt.12334","DOI":"10.1111\/bcpt.12334"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/43\/3\/genetic-influence-chemotherapy-induced-nausea-and-vomiting-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:43Z","timestamp":1763754763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/43\/3\/genetic-influence-chemotherapy-induced-nausea-and-vomiting-narrative"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.onf.389-393","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"value":"0190-535X","type":"print"},{"value":"1538-0688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,1]]}}}